Introduction
============

Carboplatin is a second-generation platinum compound developed to reduce the side effects of cisplatin, particularly neurotoxicity, nephrotoxicity and emesis, while maintaining comparable antitumor activity and effectiveness. Carboplatin is widely used to treat solid tumors in adults, especially for ovarian and lung cancer, and for several types of malignancies in children such as brain tumor, neuroblastoma, retinoblastoma, germ cell tumors, and hepatoblastoma. Moreover, the treatment protocol based upon the combination of carboplatin and vincristine reported by [@B28] seems to produce consistent and long-lasting responses in children with low grade glioma (LGG) ([@B10]; [@B35]). This is the most widely adopted chemotherapy for childhood LGG, offering high objective response rates in relapsed and newly diagnosed patients of 52 and 62%, respectively.

Carboplatin has been used with increasing frequency for the management of childhood cancers, and hypersensitivity reactions (HSRs) have consequently emerged as a significant complication of the therapy. Multiple exposures to this chemotherapeutic agent can cause sometimes life-threatening events, requiring discontinuation of treatment. However, while carboplatin-associated HSRs have been described extensively and analyzed in large cohorts of adult patients, our knowledge of their features in pediatric patients remains limited.

Incidence
=========

Allergic hypersensitivity to carboplatin is frequently reported in children, and the extensive use of carboplatin-based chemotherapy has brought with it an increase in allergic reactions ([@B1]; [@B9]; [@B20]). Carboplatin HSR has been described mostly in pediatric series of LGG, where the reported incidence is up to 47% depending on the schedules of administration ([@B19]; [@B14]).

In the initial reports on the carboplatin-vincristine combination in pediatric LGG, [@B28] observed a frequency of 7%. In a cohort of 29 children with LGG, [@B20] reported six patients (20%) who developed HSRs to carboplatin. In the retrospective, cooperative Canadian study 42% of children with LGG who received a carboplatin-based chemotherapy regimen developed HSRs during the course of the treatment ([@B19]). [@B15] observed a frequency of 40% in their study. Recently, carboplatin hypersensitivity was documented in 47% of patients by [@B14], and in the study by [@B34] of 144 children with LGG treated with carboplatin and vincristine, 56 (39%) experienced an HSR to carboplatin.

Clinical Features
=================

Carboplatin can induce mild to moderate and severe HSRs which may develop acutely during infusion or within minutes, hours, or days after the drug has been delivered.

Clinical evidence of HSRs are graded 0 through 5 (grade 5 being death) by using the NCI [@B11], CTCAE v. 4.03).

Mild and moderate reactions include all cutaneous reactions (flushing, pruritus, urticaria, angioedema, and maculopapular rash) not associated with symptoms affecting other organ systems. Severe reactions include chest pain, dyspnea, oxygen desaturation, edema/angioedema, changes in blood pressure and cardiovascular collapse.

Urticaria and facial rash may be the first and most common manifestations of hypersensitivity ([@B20]) and [@B24] reported more than 50% of patients developing at least moderately severe symptoms. Symptoms usually resolved quickly with antihistamines and steroids.

More severe reactions and systemic anaphylaxis may be life-threatening ([@B8]). It is possible that carboplatin HSRs are not always recognized. Often, the early signs are subtle and may include only a mild rash and a mild bronchospasm ([@B36]). Patients should be alerted and appropriately instructed so that symptoms are promptly recognized and the diagnosis of HSR established to prevent potentially dangerous retreatment.

Pathophysiology
===============

The exact mechanism of carboplatin HSRs remains unclear, but the different clinical patterns of allergic reactions suggest that various immunological and non-immunological mechanisms are involved ([@B38]). Likelihood of type I IgE-mediated hypersensitivity increases with the rising incidence of hypersensitivity with repeated doses and with positive skin prick test reactions to platinum compounds ([@B22]). Carboplatin can act as a hapten and cause a type I IgE-mediated, histaminergic reaction with release of inflammatory molecules ([@B26]; [@B23]). Type I IgE-mediated hypersensitivity may be linked to early onset manifestations, such as itching, chest pain, rash, and anaphylactic reactions. An alternative to the type I IgE-mediated mechanism is type IV hypersensitivity, mediated by T cells, a delayed inflammatory reaction occurring hours or days after the infusion.

Some authors have tried to predict HSRs by using skin testing ([@B38]; [@B8]). [@B38] developed a skin-test protocol for adult patients with gynecological malignancies and first demonstrated that skin testing for carboplatin made it possible to identify patients at risk for HSRs with a 99% negative predictive value. A cohort of 47 patients received a 0.02 ml intradermal injection of an undiluted aliquot of carboplatin 1 h before each course of chemotherapy. A negative skin test accurately predicted the absence of HSRs in 166 out of 168 courses of chemotherapy. [@B25] performed skin tests on 126 women with gynecological cancer 30 min before each carboplatin treatment after the sixth cycle. They reported that skin tests had been positive in six out of seven patients who later developed anaphylaxis during carboplatin re-administration, finding a 98.5% negative predictive value. Therefore, a negative carboplatin skin test seems to predict with reasonable reliability the absence of a severe HSR with subsequent infusion of the drug. However, the implications of a positive test remain less certain and the limited experience with continued treatment suggests that this approach must be undertaken with considerable caution. According to [@B20], the lack of sensitivity in skin tests could be explained by the fact that the molecular weight of carboplatin (373.272 g/mol) is low and it is not immunogenic in the native form.

Risk Factors
============

A greater risk of developing an HSR has been observed in younger patients than in older age groups of children ([@B15]); risk is also greater in girls ([@B19]) and in patients with a prior history of allergy to other drugs ([@B32]). No significant correlation was found between the occurrence of carboplatin HSRs and previous surgery, radiotherapy or tumor location ([@B15]).

The risk of hypersensitivity is related to the cumulative number of infusions rather than to the cumulative dose of carboplatin ([@B9]), thus it increases with repeated exposure to carboplatin ([@B33]; [@B37]; [@B20]; [@B36]). The first HSR generally occurs between the 7th and the 10th carboplatin infusion ([@B33]; [@B20]; [@B36]). Indeed HSRs are uncommon during the first few cycles and the incidence of reactions occurs mainly between the 7th and the 15th carboplatin infusion and may develop acutely during infusion or within minutes, hours, or days after the drug has been delivered ([@B15]).

Weekly dosing schedules of carboplatin have been identified as a risk factor for HSR in brain tumor patients ([@B37]). However, in the Canadian study ([@B19]), patients who received a weekly schedule had an incidence of HSR comparable to that of patients who were treated by monthly dosing, although HSR occurred 3 months earlier in the weekly dosing group.

According to [@B24], the threshold for the manifestation of a reaction is expected to drop with each treatment because the patient is sensitized during the first treatment, and retreatment with the same drug provides the additional immunological stimulation necessary for a reaction.

Moreover, an increased severity of HSRs might be linked to re-exposure. [@B15] reported seven out of eight patients had worsening hypersensitivity symptoms. [@B36] observed grade III or IV reactions after re-exposure in five out of nine LGG patients with initial grade II reactions. The Canadian study found that the frequency of grade III and IV reactions rose from 18.2% at the first HSR episode to 41.7% for the second episode ([@B19]). [@B14] reported grade III reactions on rechallenge in two patients who initially experienced grade I and II reactions. In the study by [@B34], 19 patients experienced a subsequent high-grade HSR (Grade III or IV) after initiating carboplatin rechallenge. In any case, [@B9] did not document any increase in severity of HSR after re-exposure. The main issue is related to the possibility that an increased severity of hypersensitivity after re-exposure might expose the patient to the risk of anaphylaxis ([@B18]; [@B37]).

Management
==========

Chemotherapy protocols based on a combination of carboplatin and other drugs produced good results in terms of progression-free survival rate, as in LGG. Thus, when a patient shows a response to a carboplatin-based regimen, strategies that alter the HSRs may be justified as an attempt to salvage an effective therapy.

However, when HSRs occur early in treatment, it may be harder to predict the response to treatment and the benefit of continuing carboplatin may be inferior to the risk of a more severe allergic reaction. Therefore, according to International Society of Pediatric Oncology LGG protocol, in patients developing an allergy to carboplatin during consolidation, therapy shall be continued with alternative drug combinations (cisplatin/vincristine and cyclophosphamide/vincristine) ([@B3]). The substitution of carboplatin with another platinum compound (such as cisplatin) may be limited by cross-reactivity of platinum-specific IgE ([@B29]). The cisplatin and cyclophosphamide combination showed efficacy when alternated with carboplatin in the French "BABY-SFOP" LGG study ([@B31]). Despite its effectiveness, however, cisplatin is more ototoxic and nephrotoxic than carboplatin ([@B4]). In patients receiving carboplatin, the incidence of ototoxicity is approximately 7% ([@B13]; [@B17]). In patients receiving cumulative cisplatin doses of ≤200 mg/m^2^, 200--400 mg/m^2^, and ≥400 mg/m^2^, the incidence increases to 59, 68, and 65%, respectively ([@B30]). Moreover, severe nephrotoxicity has not been reported during carboplatin-therapy and reduction of glomerular filtration rate to less than 50% is less frequent than with cisplatin. Moreover, cisplatin combined with cyclophosphamide could further damage renal function, therefore, in order to limit cumulative doses of these agents, no more than five cycles of both combinations shall be given. Therefore, to date the vincristine/carboplatin combination remains the most widely adopted multi-agent chemotherapy for childhood LGG. Of course, in patients sensitive to carboplatin the benefit of continuing this agent must be traded off against the risk of more severe reactions in view of the fact that no precise way to identify patients likely to react or to predict the severity of the reactions has yet been found.

To date, various desensitization and/or premedication protocols have been proposed, in children developing carboplatin HSR as a late event.

Pretreatment with steroids or antihistamines usually fails to prevent IgE-mediated reactions. The effectiveness of oral antihistamines has been found only in mild or moderate cases of carboplatin HSRs ([@B15]); moreover, the prolonged use of steroids is associated with long-term side effects in children and adolescents, such as mood changes, weight gain, and osteoporosis ([@B19]). The literature points to a low efficacy of premedication alone in re-exposure to carboplatin in patients with HSR. [@B2] and [@B16] have reported complete failure of premedication (100% discontinuation rate). In [@B9] and [@B36] the effectiveness of premedication was 20 and 28.6%, respectively.

To date, several desensitization protocols for re-administering carboplatin have been implemented and have produced promising results ([@B24]; [@B20]; [@B21]; [@B7]) (**Table [1](#T1){ref-type="table"}**). Drug desensitization is a procedure designed to obtain temporary clinical tolerance, especially in cases where the patient seems to have benefited from the drug ([@B6]; [@B21]; [@B7]). The complete target dose of the drug is administered in separate incremental steps in order to obtain an inhibition of mast-cell activation for the specific drug antigen. Sometimes this procedure is accompanied by a more intense premedication to prevent any risk of reaction ([@B15]). It is possible that the administration of small, increasing doses of antigen delivered at fixed time intervals may consume IgE antibodies slowly without acute reactions by inducing a prolonged hypo-responsiveness to triggering doses of the desensitizing antigen. Successful re-exposure to carboplatin is defined as the ability to complete the full planned course of treatment. All other cases where carboplatin is discontinued are considered a failure of re-exposure.

###### 

Success rate of desensitization in patients with hypersensitivity reactions to carboplatin.

  Studies   No. of patients treated with carboplatin   Patients with HSR (No./%)   Patients re-exposed to carboplatin (No./%)   No. of patients re-exposed with desensitization protocol   Success rate of desensitization (%)
  --------- ------------------------------------------ --------------------------- -------------------------------------------- ---------------------------------------------------------- -------------------------------------
  [@B20]    29                                         6 (20.6%)                   6 (100%)                                     6                                                          6/6 (100%)
  [@B19]    105                                        44 (41.9%)                  34 (77.2%)                                   12                                                         1/12 (8.3%)
  [@B15]    50                                         20 (40%)                    19 (95%)                                     9                                                          6/9 (66.6%)
  [@B14]    59                                         16 (27.1%)                  10 (62.5%)                                   10                                                         2/10 (20%)
  [@B34]    144                                        56 (38.9%)                  55 (98.2%)                                   25                                                         19/25(76%)

In [@B20] described a successfully modified desensitization protocol for carboplatin administration in six children who had an allergic reaction to the drug. The protocol consisted of a standard dose of carboplatin (175 mg/m^2^ in 100 ml saline solution) at an increasing infusion rate, without premedication. The drug was administered every 30 min starting with a dose of 0.3 mg/m^2^/min and reaching 2.4 mg/m2/min in five steps ([@B20]) (**Table [2](#T2){ref-type="table"}**). The protocol allowed the patients to receive carboplatin without adverse reactions in all re-treated patients. [@B15] (**Table [2](#T2){ref-type="table"}**) implemented a seven-step desensitization protocol in nine children affected by LGG, with a success rate of 66.6%. Patients were premedicated with pheniramine maleate (1 mg/kg/dose IV) and dexamethasone (0.3 mg/kg/dose IV) and the drugs were infused progressively every 15 min, beginning with a 0.1 mg/dose bolus, up to a 25 mg/dose. In the study by [@B34] patients were re-exposed to therapy with carboplatin using precautionary measures, which included: prolongation of infusion (1--2 h); premedication with H1 antagonists; H2 antagonists, and corticosteroids. In patients with recurrent reactions despite precautionary measures, and in patients in which the first reaction was considered severe, a desensitization scheme was proposed which involved the administration of carboplatin in gradually increasing doses, from as low as 0.01 mg/min up to a maximum of 1.5 mg/min in nine progressive increments (**Table [2](#T2){ref-type="table"}**). The success rate was 76%.

###### 

Effective desensitization protocols.

  [@B20]   [@B15]   [@B34]                                   
  -------- -------- -------- --- ----------- ---- --- ------ ----
  1        0.3      30       1   0.1         15   1   0.01   15
  2        0.6      30       2   1           15   2   0.1    15
  3        1.2      30       3   2.5         15   3   0.5    15
  4        1.8      30       4   5           15   4   1      15
  5        2.4      30       5   10          15   5   1      15
                             6   25          15   6   1      15
                             7   Remaining   15   7   1      15
                                 dose             8   1.5    15
                                                  9   1.5    15

However, according to [@B19] and [@B14], the desensitization protocol demonstrated low efficacy, due to differences in starting dose, infusion rate and number of increments compared with other studies. In the Canadian study, the desensitization protocol consisted of a progressive increase in the rate of carboplatin infusion over various periods (from 1 h to 6 h) according to previously described schedules (doses of 1, 2.5, 5, 10, 25, and 50 mg of carboplatin infused at 1 mg/min every 15 min; the remainder of the dose was infused at the standard rate of 200 mg/h) ([@B5]; [@B27]). Nevertheless, among the 12 patients who underwent desensitization and premedication (antihistamine with or without corticosteroid initiated from 3 days to 1 h before carboplatin infusion), only one patient (8.3%) was able to complete his carboplatin therapy ([@B19]). In this study the lower success rate of desensitization may be due to the starting dose being higher than in other studies ([@B20]; [@B15]; [@B34]). [@B14] reported a success rate of 20%. All patients received premedication with dexamethasone (between 0.05 and 0.15 mg/kg delivered via IV 1 h prior to carboplatin) and cetirazine (∼0.2 mg/kg delivered orally 1 h prior to carboplatin) and all but one, were exposed to the desensitization diagram with subsequent infusions of increasing doses of carboplatin according to the scheme described by [@B12]. The protocol consisted of an initial infusion of 1/1000 of the total dose in the first 90 min, followed by 1/100 of the total dose for an additional 90 min, up to 1/10 in 90 min and the remainder of the dose in the last 90 min. Desensitization was not effective in this cohort. It is not clear why the success rate is so different from what was previously reported in adult literature. This may be due to the lack of a gradual increase in the rate of infusion (from 0.6 mg/m^2^/min to 5.5 mg/m^2^/min in the fourth step), and to the limited number of increments.

Conclusion
==========

As carboplatin has been used with increasing frequency for the management of childhood cancers, HSRs have emerged as a significant complication of the therapy although their features involving pediatric patients remain limited. HSRs occur mainly between the 7th and the 15th carboplatin infusion, therefore attention must be paid to the cumulative number of infusions rather than to the cumulative dose.

When a patient shows a response to a carboplatin-based regimen, strategies that alter the HSRs may be justified as an attempt to salvage an effective therapy, although the benefits of continuing the carboplatin chemotherapy should always be carefully weighed against the risks of potential dangerous complications.

Patients with an early onset allergic reaction should switch to alternative chemotherapy regimens that offer a good efficacy rate in order to avoid any risk associated with re-exposure. Thus, the likelihood of completing therapy is higher if restricted to patients with a late onset reaction.

Premedication with anti-histamines and/or corticosteroids is able to prevent an allergic reaction only in a limited number of patients with mild or moderate reactions. Several desensitization protocols have been implemented in order to re-administer carboplatin with various efficacy results. Hypothesis on their effectiveness to be further investigated are based on the potential role of the starting dose, infusion rate and number of increments. A lower starting dose, a slow infusion, and a number of increments greater than or equal to 4 are associated with a greater probability of success.
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